Traitement Sclérose en plaques en Espagne — recevez 3 correspondances personnalisées de cliniques

Nonresidents generally do not receive free multiple sclerosis treatment in Spain. Access to the public healthcare system requires legal residency and social security contributions. European Union citizens may use the European Health Insurance Card for emergency care. Long-term disease-modifying therapies usually require private payment.

• Healthcare access: Public care requires a Spanish health card and social security number.
• EU card coverage: The European Health Insurance Card covers acute flares and emergencies only.
• Private medication costs: Therapies like Ocrevus can cost $25,000 to $40,000 annually for self-payers.
• Specialist consultations: Private neurology visits in Spain typically range from $65 to $130.

Bookimed Expert Insight: Patients seeking advanced care can find unique opportunities at Quironsalud Madrid. This center conducts research into neurodegenerative disorders and occasionally offers free treatment through clinical trials. This is a rare way for nonresidents to access high-cost therapies without the standard private fees.

Patient Consensus: Patients note that while Spanish care is excellent, foreigners often pay $15,000 to $50,000 annually. Many suggest joining local support groups to navigate the complex transition to the public system.

Spain is a global hub for multiple sclerosis care with top-rated centers in Barcelona and Madrid. Respected facilities include the Multiple Sclerosis Center of Catalonia at Vall d'Hebron and JCI-accredited private hospitals like Centro Médico Teknon and Hospital Ruber Internacional. These institutions offer advanced immunotherapies and clinical trials.

• Specialized centers: The Multiple Sclerosis Center of Catalonia (Cemcat) is the largest dedicated facility.
• Expert neurologists: Dr. Anna Pujol at Teknon has over 35 years of clinical experience.
• Research leadership: Dr. Rafael Arroyo González at Quirónsalud Madrid leads over 100 clinical trials.
• Advanced therapies: Clinics provide Ocrevus infusions, natalizumab, and specialized plasma exchange therapy protocols.

Bookimed Expert Insight: While many choose Barcelona for its research centers, our data shows Quirónsalud Torrevieja serves 120,000 patients annually. This high volume often translates to faster access for international patients compared to city-center public waits. For complex cases, choosing a JCI-accredited clinic like Ruber Internacional ensures access to 40+ specialized departments under one roof.

Patient Consensus: Patients note that private clinics like those in the Quirónsalud network provide much faster access to infusions. Many appreciate having the same doctor for both public research trials and private follow-up care.

Spain provides routine access to a full range of European Medicines Agency (EMA) approved Disease-Modifying Therapies (DMTs). Patients can access first-line orals like Dimethyl fumarate, injectables such as Glatiramer acetate, and high-efficacy infusions including Ocrelizumab (Ocrevus) and Natalizumab. The public system typically covers these treatments.

• First-line orals: Dimethyl fumarate and Teriflunomide are frequently prescribed as initial treatments.
• Injectable therapies: Interferon beta-1a, Interferon beta-1b, and Glatiramer acetate remain standard options.
• High-efficacy infusions: Ocrelizumab, Natalizumab, and Ofatumumab are routinely available for aggressive cases.
• Second-line orals: Fingolimod and Cladribine are used for highly active relapsing MS.

Bookimed Expert Insight: Clinical trial access is a major differentiator in Spain. Quironsalud Madrid and Centro Médico Teknon actively run trials for neurodegenerative disorders. Patients may access next-generation therapies like tolebrutinib through these programs before general approval. This is vital when standard DMTs show limited results.

Patient Consensus: Patients note that while approval for high-efficacy infusions is reliable, waiting periods for scheduling can vary by region. Many emphasize that starting with a neurologist like Dr. Anna Pujol in Barcelona helps streamline the complex diagnostic process.

Expats in Spain can see an MS neurologist within 1 to 14 days through the private healthcare sector. Public system wait times typically range from 1 to 6 months after a GP referral. Immediate access is available at JCI-accredited centers in Madrid, Barcelona, and Alicante.

• Private wait times: Appointments are typically secured within 1 or 2 weeks at private facilities.
• Public system access: Specialist queues average 1 to 6 months depending on the specific region.
• Urgent cases: Requesting an urgente referral can reduce public wait times to 2–4 weeks.
• Specialized centers: Facilities like Centro Médico Teknon and Quironsalud Madrid provide rapid diagnostic access.

Bookimed Expert Insight: Spain’s private hospital networks like Quirónsalud and HM Hospitales serve over 2,000,000 outpatients annually. Data shows that clinics in Mediterranean hubs like Torrevieja or Marbella often have shorter queues than crowded Madrid centers. Choosing a high-volume private facility remains the most reliable way to bypass the standard 90-day public specialist guarantee.

Patient Consensus: Patients note that arriving with translated MRI scans and medical records is essential for a productive first visit. Many highlight that private doctors like Dr. Anna Pujol are exceptionally helpful and often provide multilingual support.